04K:F Knight Therapeutics Inc

EUR 3.86 -0.04 -1.025641
Icon

Knight Therapeutics Inc (04K:F) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 3.86

-0.04 (-1.03)%

EUR 0.39B

100.00

N/A

N/A

Icon

04K:F

Knight Therapeutics Inc (EUR)
COMMON STOCK | F
EUR 3.86
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.39B

N/A

EUR 3.86

Knight Therapeutics Inc (04K:F) Stock Forecast

N/A

Based on the Knight Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Knight Therapeutics Inc is not available over the next 12 months. Knight Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Knight Therapeutics Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Knight Therapeutics Inc’s stock price was EUR 3.86. Knight Therapeutics Inc’s stock price has changed by -0.52% over the past week, -6.31% over the past month and +12.87% over the last year.

No recent analyst target price found for Knight Therapeutics Inc
No recent average analyst rating found for Knight Therapeutics Inc

Company Overview Knight Therapeutics Inc

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib f...Read More

https://www.gud-knight.com

3400 De Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8

725

December

EUR

Germany

Adjusted Closing Price for Knight Therapeutics Inc (04K:F)

Loading...

Unadjusted Closing Price for Knight Therapeutics Inc (04K:F)

Loading...

Share Trading Volume for Knight Therapeutics Inc Shares

Loading...

Compare Performance of Knight Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 04K:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Knight Therapeutics Inc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRKC:F
MERCK KGAA NAM.SP.ADR +0.40 (+1.19%) EUR72.39B N/A 13.13

ETFs Containing 04K

Symbol Name 04K's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Knight Therapeutics Inc (04K:F) Stock

Stock Target Advisor's fundamental analysis for Knight Therapeutics Inc's stock is Neutral.

Unfortunately we do not have enough data on 04K:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 04K:F's stock to indicate what its average analyst target is.

04K:F stock's Price/Earning ratio is 41.06. Our analysis grades 04K:F stock's Price / Earning ratio at F. This means that 04K:F stock's Price/Earning ratio is above 74% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange. Based on this 04K:F may be a overvalued for its sector.

The last closing price of 04K:F's stock was EUR 3.86.

The most recent market capitalization for 04K:F is EUR 0.39B.

Unfortunately we do not have enough analyst data on 04K:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Knight Therapeutics Inc's stock.

As per our most recent records Knight Therapeutics Inc has 725 Employees.

Knight Therapeutics Inc's registered address is 3400 De Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8. You can get more information about it from Knight Therapeutics Inc's website at https://www.gud-knight.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...